Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$5.79 USD
+0.04 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $5.78 -0.01 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.79 USD
+0.04 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $5.78 -0.01 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Zacks News
Aldeyra Therapeutics Inc (ALDX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Aldeyra Therapeutics Inc (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aldeyra's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aldeyra Therapeutics.
Company News for Apr 15, 2020
by Zacks Equity Research
Companies in the news are: WFC, FAST, FRC, ALDX
What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Buy Stock
by Zacks Equity Research
Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
by Zacks Equity Research
Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.
Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock
by Zacks Equity Research
Aldeyra (ALDX) needs investors to pay close attention to the stock based on moves in the options market lately.
Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) shares rose nearly 8% in the last trading session, amid huge volumes.
Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap
by Zacks Equity Research
Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.
Implied Volatility Surging for Aldeyra Therapeutics (ALDX) Stock Options
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) needs investors to pay close attention to the stock based on moves in the options market lately.
Sucampo Pharmaceuticals (SCMP) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
Sucampo Pharmaceuticals(SCMP) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) saw a big move last session, as its shares jumped more than 34% on the day, amid huge volumes.
Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet
by Zacks Equity Research
Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.
Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data
by Zacks Equity Research
Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study
Horizon (HZNP) Sells European Rights for Procysbi & Quinsair
by Zacks Equity Research
Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.
Roche's Arthritis Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
by Zacks Equity Research
Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.
Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.
AstraZeneca Sells Marketing Rights to Seloken in Europe
by Zacks Equity Research
AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.